Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 10 EP applications Raymond Stevenson Gairns has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 18, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12832680

METHODS AND COMPOSITIONS FOR TREATING, REVERSING, INHIBITING OR PREVENTING RESISTANCE TO ANTIPLATELET THERAPY

IPC classification:
A61K 31/20
Agent:
Sarah Elizabeth Roques, J A Kemp
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP12795842

COMBINATION TREATMENT OF CANCER

IPC classification:
A61K 31/519, A61P 13/08, A61P 35/00
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP13715426

HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS

IPC classification:
A61K 31/439, A61P 31/04, C07D 471/08
Applicant:
AstraZeneca AB
Agent:
Anthony James Proctor, Potter Clarkson LLP
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP13198224

Certain triazolopyrazines, compositions thereof and methods of use therefor

IPC classification:
A61K 31/437, A61K 31/4985, A61P 35/00, C07D 471/04, C07D 487/04, C07D 519/00
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13718618

CRYSTALLINE FORMS OF (S) -4-AMINO-N- (1- (4 - CHLOROPHENYL) - 3 - HYDROXYPROPYL) -1- (7H - PYRROLO [2, 3-D]PYRIMIDI N-4-YL) PIPERIDINE-4-CARBOXAMIDE

IPC classification:
A61K 31/519, A61P 35/00, C07D 487/04
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP13821906

PHARMACEUTICAL FORMULATION OF N- [5- [2-(3,5-DIMETHOXYPHENYL) ETHYL]-2H-PYRAZOL-3-YL]-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/46, A61K 31/496
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP15170608

CERTAIN TRIAZOLOPYRIDINES, COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CANCER.

IPC classification:
A61K 31/437, A61K 31/4985, A61P 35/00, C07D 471/04, C07D 487/04, C07D 519/00
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
EXAMINATION IN PROGRESS
EP11805575

PURINE DERIVATIVES

IPC classification:
A61K 31/522, C07D 473/18
Applicant:
AstraZeneca AB
Applicant:
Sumitomo Dainippon Pharma Co., Ltd.
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
PATENT GRANTED
EP11805574

IMIDAZO[4,5-C]QUINOLIN-1-YL DERIVATIVE USEFUL IN THERAPY

IPC classification:
A61K 31/4188, A61K 31/4745, A61P 1/16, A61P 11/06, A61P 17/04, A61P 17/06, A61P 17/12, A61P 31/04, A61P 31/12, A61P 31/18, A61P 37/08, C07D 471/04
Applicant:
AstraZeneca AB
Applicant:
Sumitomo Dainippon Pharma Co., Ltd.
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15726257

METHOD FOR SUPPRESSING GLUCAGON SECRETION OF AN SGLT2 INHIBITOR

IPC classification:
A61K 31/155, A61K 31/40, A61K 31/403, A61K 31/4985, A61K 31/522, A61K 31/70, A61K 31/7042, A61K 38/28, A61P 3/10
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature